Clavam 625mg (Amoxicillin+Clavulanate) London — Broad-Spectrum Antibiotic UK 2026

❓ FAQ 1: How does Clavam 625mg treat acute exacerbations of COPD in London's high-COPD boroughs?

London's inner city boroughs — particularly Hackney, Tower Hamlets, Lewisham, and Southwark — have COPD rates 2-3 times higher than national averages, reflecting historical industrial pollution, smoking legacy, and socioeconomic deprivation. Acute exacerbations of COPD (AECOPD) — characterised by increased breathlessness, cough, and purulent sputum — are caused by bacterial infection in approximately 50% of cases, most commonly Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Haemophilus and Moraxella frequently produce beta-lactamase — making plain Amoxicillin inadequate for many AECOPD cases in London's antibiotic-experienced COPD population. Clavam 625mg's Amoxicillin-Clavulanate combination covers these beta-lactamase-producing organisms with the bactericidal activity that clears the infection and resolves exacerbations faster than no antibiotic treatment. London's NICE CG191 guidelines recommend antibiotic therapy for AECOPD with purulent sputum — Clavam 625mg three times daily for 5 days is consistent with these recommendations. London's King's College Hospital and Royal London Hospital respiratory medicine units manage complex AECOPD patients requiring Clavam alongside bronchodilator and steroid therapy.

❓ FAQ 2: What skin and soft tissue infections in London's diverse community benefit specifically from Clavam 625mg?

Skin and soft tissue infections (SSTIs) in London's diverse population present across a wide spectrum of pathogens and severity. Clavam 625mg's broad spectrum is specifically valuable for: animal bite wounds — dog and cat bites carry Pasteurella multocida (cat bites primarily), Capnocytophaga canimorsus, Streptococcus, and anaerobes; all bite wounds warrant Clavam 625mg for prophylaxis or treatment because of the polymicrobial nature and the beta-lactamase-producing Pasteurella that plain Amoxicillin cannot cover. London's veterinary population and diverse pet-owning community creates substantial bite wound prescribing. Infected eczema — common in London's South Asian and African Caribbean communities with high atopic dermatitis prevalence — often involves Staphylococcus aureus and Streptococcus that respond to Clavam. Diabetic foot infections — polymicrobial with aerobic and anaerobic organisms — require Clavam's combined spectrum as the oral therapy of choice for mild-moderate infections. And infected surgical wounds in post-operative London patients — where both skin organisms and surgical flora require coverage — benefit from Clavam's comprehensive antibacterial spectrum. UCLH and Guy's Hospital London's wound care teams prescribe Clavam for these mixed-flora SSTI scenarios.

❓ FAQ 3: How does Clavam 625mg treat sinusitis in London's dust-exposed and air-quality-affected population?

London's persistent air quality challenges — nitrogen dioxide from heavy traffic, PM2.5 particulates, and seasonal pollen — create a high burden of rhinitis and sinusitis exacerbation. Acute bacterial sinusitis (as opposed to the more common viral sinusitis, which doesn't require antibiotics) — characterised by symptoms persisting beyond 10-12 days, or severe headache and facial pain with fever — is caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. NICE guidelines recommend delaying antibiotic prescribing for most sinusitis presentations by 10-14 days (as most resolve without antibiotics) — but when antibiotics are indicated, Amoxicillin remains first-line for uncomplicated sinusitis. Clavam 625mg is specifically recommended when: sinusitis doesn't respond to plain Amoxicillin after 5-7 days (suggesting beta-lactamase-producing Haemophilus or Moraxella); when there is clinical severity warranting broader coverage; or in immunocompromised London patients where untreated sinusitis carries higher complication risk. London's ENT specialists at the Royal National ENT Hospital prescribe Clavam for second-line or initial severe sinusitis specifically for this spectrum advantage.

❓ FAQ 4: What is the evidence for Clavam 625mg versus Augmentin 625mg — are they truly equivalent?

Clavam 625mg and Augmentin 625mg contain identical active ingredients at identical doses — Amoxicillin 500mg and Clavulanic Acid 125mg — and are bioequivalent products. Generic medicines including Clavam undergo regulatory bioequivalence testing demonstrating that the drug reaches the same blood concentration over the same time period (AUC and Cmax within 80-125% of the reference product). Both products have the same mechanism of action, spectrum of antibacterial activity, dosing frequency, duration of treatment, side effect profile, and clinical outcomes. The only differences are in inactive excipients (fillers, binders, coatings), packaging, and price. For London's NHS-registered patients, both are dispensed under the generic name "co-amoxiclav" — the NHS doesn't differentiate between Augmentin and generic equivalents like Clavam. For London's private patients or international visitors purchasing directly, Clavam 625mg from Unnati Pharmax with WHO-GMP certification provides the same clinical benefit as brand Augmentin at dramatically reduced cost — the WHO-GMP certification confirming manufacturing quality equivalent to brand manufacturing standards.

❓ FAQ 5: How does London's antimicrobial stewardship programme manage Clavam prescribing and what role do patients play?

NHS England's antimicrobial stewardship (AMS) programme — implemented through London's 33 CCG/ICB areas — aims to optimise antibiotic use, preserve effectiveness, and reduce resistance. Key Clavam-specific stewardship principles in London's primary care: treat bacterial infections only — Clavam is ineffective against viral URIs (colds, flu, COVID) and should not be prescribed for these despite patient pressure; use the narrowest appropriate spectrum — if plain Amoxicillin covers the likely organism, Clavam's clavulanate adds unnecessary GI side effects and ecological disruption; shortest effective course — 5-7 days for most SSTI and respiratory indications, not the historical 10-14 days; and delayed prescriptions — giving patients a Clavam prescription to fill only if symptoms don't improve after 48-72 hours, avoiding antibiotic use in the majority who recover without them. London patients play an active role in AMS by: not requesting antibiotics for viral illness; completing prescribed courses without stopping early or saving tablets for later; and never sharing antibiotics. The UKHSA's "Keep Antibiotics Working" campaign actively engages London's diverse communities in antimicrobial stewardship messaging tailored to different cultural contexts.